Clinical Management of Obesity Worldwide

Publishing in November 2010:

Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2009-2019

– 300 pages  – 95 Exhibits  – 54 Company Profiles  – February 2011  – Report #S835

Order online or via order form.
(Save $1,000 with advance price discount)

[This report description and table of contents is also available at report S835.]

This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. The report profiles 60 of the leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.

Preliminary Table of Contents


1.1 Clinical Diagnosis of Obesity
1.1.1 Body Mass Index Scale
1.1.2 Measuring BMI vs. Measuring Adiposity
1.1.3 Classification of Obesity
1.1.4 Overweight, Obesity, Morbid Obesity, Super Obesity
1.1.5 Genetic Testing for Obesity
1.2 Obesogenic Influences
1.2.1 Dietary Changes Over the Last Twenty Years
1.2.2 Sedentary Lifestyles
1.2.3 Ongoing Research into Causes
1.3 Metabolic Pathways of Energy Homeostasis
1.3.1 Role of the Hypothalamus
1.3.2 Role of the Stomach
1.3.3 Role of the Small Intestine
1.3.4 Role of the Pancreas
1.3.5 Role of Adipose Tissue, An Endocrine Organ
1.3.6 Other Peptides
1.3.7 Obesity as Survival Mechanism
1.4 Co-Morbidities of Overweight and Obesity
1.4.1 Metabolic Syndrome
1.4.2 Effects of Obesity on Immune Function
1.4.3 Racial Differences in Co-morbidities
1.4.4 Type 2 Diabetes and Insulin Resistance
1.4.5 Hypertension
1.4.6 Dyslipidemia
1.4.7 Depression
1.4.8 Osteoarthritis
1.4.9 Asthma
1.4.10 Sleep apnea
1.4.11 Obesity and Cancer
1.5 Global Incidence and Prevalence of Obesity
1.5.1 By Geographic Region USA, Canada, Mexico, Brazil European Union Asia-Pacific
1.5.2 By Age Group Incidence and Prevalence among Children Incidence and Prevalence among Elderly
1.5.3 Incidence and Prevalence of Morbid Obesity
2.1 Costs Related to Treating Obesity and Co-Morbidities
2.1.1 Current Healthcare Expenses
2.1.2 Breaking the Bank: Predictions of Future Healthcare Expenses
2.1.3 Healthcare Reform and Obesity
2.2 Impact on Businesses
2.2.1 Increased Health Insurance Costs
2.2.2 Increase in Workers’ Compensation Costs
2.2.3 Debate: Pay Employees to Lose Weight?
2.3 Legislating Prevention and Weight Loss
2.3.1 Changing Society: Educating Children as well as Adults
2.3.2 Pressure on the Food Industry
3.1 Role of Behavior Modification and Lifestyle Changes
3.1.1 Behavior Modification Programs: Decidedly Mixed Success
3.1.2 Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)
3.1.3 Why Diets Usually Fail
3.2 Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs
3.2.1 The Bloom is Off the Rose: Promising Drugs Which Have Failed, and Why
3.2.2 Drugs Currently on the Market Appetite Suppression Drugs Malabsorption Drugs Satiety Drugs Combination Drugs
3.2.3 Areas of Pharmaceutical Research Melanocortin Receptor System
3.2.4 Drugs in the Pipeline—But Will They Hold Up? Appetite Suppression Drugs Malabsorption Drugs Satiety Drugs Combination Drugs
3.2.5 Safety: The Major Diet Drug Hurdle
3.2.6 After ‘Phen-Fen’ Experience, Will Physicians Prescribe Off-Label Combinations?
3.3 Non- Pharmaceutical Options for Treating Obesity
3.3.1 Permanent Surgical Modification
3.3.2 Surgical Revision of Bariatric Procedures
3.3.3 Short-Term Surgical/Device Solutions
3.3.4 Invasive Devices to Treat Obesity Devices to Restrict Stomach Volume Artificial Fullness Devices Malabsorption Devices Devices to Control Gastric Emptying Appetite Suppressive Devices
4.1 Global Market for the Treatment of Obesity
4.1.1 Pharmaceuticals Satiety Malabsorption Appetite Suppression Combination Drugs
4.1.2 Devices Stomach Restriction Artificial Fullness Malabsorption Gastric Emptying Appetite Suppression
4.2 Market Shares of Leading Companies
4.2.1 Leading Pharmaceutical Companies
4.2.2 Leading Device Companies
4.3 Americas Market for the Treatment of Obesity
4.3.1 USA
4.3.2 Canada
4.3.3 Mexico
4.3.4 Brazil
4.4 European Market for the Treatment of Obesity
4.4.1 United Kingdom
4.4.2 France
4.4.3 Germany
4.4.4 Italy
4.4.5 Spain
4.4.6 Rest of Europe
4.5 Asia-Pacific Markets for the Treatment of Obesity
4.5.1 Japan
4.5.2 India
4.5.3 China
4.5.4 Australia
4.5.5 Russia
4.6 ROW Markets for the Treatment of Obesity
4.7 Market Drivers and Restraints
4.7.1 Drivers
4.7.2 Restraints
4.8 Marketing Opportunities
5.1 Abbott Laboratories
5.2 Allergan
5.3 Amylin Pharmaceuticals
5.4 Arena Pharmaceuticals
5.5 AstraZeneca
5.6 BAROnova Therapeutics
5.7 BaroSense
5.8 Covidien
5.9 CR Bard, Inc.
5.10 Eli Lilly & Company
5.11 EndoGastric Solutions
5.12 EndoSphere
5.13 EndoVx
5.14 EnteroMedics
5.15 Ethicon Endo-Surgery (JNJ)
5.16 Gelesis, Inc.
5.17 GI Dynamics
5.18 GlaxoSmithKline
5.19 Helioscopie
5.20 Interleukin Genetics
5.21 IntraPace
5.22 Merck
5.23 Nestlé Healthcare Nutrition
5.24 NeuroSearch A/S
5.25 Novo Nordisk
5.26 Orexigen
5.27 Pfizer
5.28 ReShape Medical
5.29 Rhythm Pharmaceuticals
5.30 SafeStitch Medical, Inc.
5.31 Sanofi Aventis
5.32 Satiety
5.33 Scientific Intake, LLC
5.34 Silhouette Medical, Inc.
5.35 Spatz FGIA, Inc.
5.36 USGI Medical
5.37 ValenTx, Inc.
5.38 Verva Pharmaceuticals Ltd.
5.39 Vivus, Inc.
Company Contact Details
Terms and Abbreviations Used in this Report

Leave a Reply